FindTrial
Sign In

The Role and Mechanisms of Langerin in Epicutaneous Sensitization of Atopic Dermatitis

The Role and Mechanisms of Langerin in Epicutaneous Sensitization of Atopic Dermatitis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-CCC-14004828
Enrollment
Unknown
Registered
2014-05-05
Start date
2014-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

TSLP stimulation:anti-MYD88 + anti-IgE receptor
No TSLP stimulation:anti-MYD88 + anti-IgE receptor

Sponsors

Institute of Dermatology, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 80 Years

Inclusion criteria

Inclusion criteria: The diagnosis of AD according to Williams' criteria, disease severity was assessed quantitatively with SCORAD from mild to severe AD. Volunteered for this study and signed informed consent.

Exclusion criteria

Exclusion criteria: ?Pregnant or lactating females; Any other situations not suitable for this study determined by the investigators.

Design outcomes

Primary

MeasureTime frame
Langerin express on MoLCs of AD;the binding abilities of Langerin and allergy(OD;activation index of Langerhans cell;polarization index of T cell;—

Countries

China

Contacts

Public ContactYao Xu

Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College

dryao_xu@126.com+86 13512513536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026